Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of
dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will
involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous
histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced
solid tumours (except sarcomas).